Aerete Integrative Medicine LLC
Aerete Integrative Medicine LLC was paid $2.05M by Medicaid between Jan 2018 and Jun 2021, across 36 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 41% of everything it billed.
JEFFERSONVILLE, IN 47130
Next to other Clinical Social Worker providers in Indiana
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,912 | $215K | |
| 2019 | 16,286 | $871K | |
| 2020 | 14,844 | $821K | |
| 2021 | 4,221 | $145K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 41% | 5,460 | 2,806 | $841K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 17% | 8,470 | 4,285 | $356K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 17% | 3,191 | 1,814 | $346K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 16% | 11,911 | 6,323 | $336K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 4.9% | 1,845 | 1,292 | $100K |
| 80305 | 1.2% | 2,663 | 1,759 | $24K | |
| 99406 | <1% | 3,316 | 1,744 | $18K | |
| 99401 | <1% | 993 | 541 | $13K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 184 | 133 | $8K |
| 81025 | <1% | 795 | 624 | $4K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 64 | 55 | $4K |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | <1% | 41 | 31 | $2K |
24 more codes
| 36415 | Collection of venous blood by venipuncture | <1% | 50 | $107.98 |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 26 | $21.96 |
| 80357 | 0% | 57 | $0.00 | |
| 80349 | 0% | 57 | $0.00 | |
| 80368 | 0% | 57 | $0.00 | |
| 80358 | 0% | 57 | $0.00 | |
| 80353 | 0% | 57 | $0.00 | |
| 80367 | 0% | 57 | $0.00 | |
| 80359 | 0% | 57 | $0.00 | |
| 80324 | 0% | 57 | $0.00 | |
| 80356 | 0% | 57 | $0.00 | |
| 80354 | 0% | 57 | $0.00 | |
| 80373 | 0% | 57 | $0.00 | |
| 80361 | 0% | 57 | $0.00 | |
| 80346 | 0% | 57 | $0.00 | |
| 80365 | 0% | 57 | $0.00 | |
| 83992 | 0% | 57 | $0.00 | |
| 80360 | 0% | 57 | $0.00 | |
| 80362 | 0% | 57 | $0.00 | |
| 80370 | 0% | 57 | $0.00 | |
| 80348 | 0% | 57 | $0.00 | |
| 80372 | 0% | 57 | $0.00 | |
| 80355 | 0% | 57 | $0.00 | |
| 80366 | 0% | 57 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.